Of EGFR-TKI nonresponders, 20% to 30% were noted in NSCLC patients with EGFR mutations receiving EGR-TKIs therapy.[9,10,19] In EGFR-TKI nonresponders, inferior PFS and OS were observed compared with EGFR-TKI responders. Here, EGFR is linked to non-small cell lung carcinoma.